Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 105

Results For "report"

2004 News Found

Nectar Lifesciences’ suo moto clarification on a news item
News | March 07, 2024

Nectar Lifesciences’ suo moto clarification on a news item

Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs


Briefs: SMS Pharmaceuticals and Vimta Labs
News | March 03, 2024

Briefs: SMS Pharmaceuticals and Vimta Labs

EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility


Ministry of Ayush signed MoU with Research and Information System for Developing Countries
Policy | February 28, 2024

Ministry of Ayush signed MoU with Research and Information System for Developing Countries

Academic and Policy Research to get further boost, RIS will bring forth Ayush Service Sector report soon


Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows achieved groundbreaking results in liver disease due to MASH
Clinical Trials | February 28, 2024

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows achieved groundbreaking results in liver disease due to MASH

Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis


Concord Biotech receives GMP certificate from Kenya regulator
Drug Approval | February 26, 2024

Concord Biotech receives GMP certificate from Kenya regulator

The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series


Zydus receives WHO prequalification for Miltefosine formulation and API
Drug Approval | February 26, 2024

Zydus receives WHO prequalification for Miltefosine formulation and API

Leishmaniasis is caused by protozoan parasites which are transmitted by the bite of infected female phlebotomine sandflies


Moderna posts Q4 2023 revenue at US$ 2.8 billion
News | February 23, 2024

Moderna posts Q4 2023 revenue at US$ 2.8 billion

Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance


Pfizer and AIF’s Project Parivartan demonstrates progress in addressing antimicrobial resistance
News | February 22, 2024

Pfizer and AIF’s Project Parivartan demonstrates progress in addressing antimicrobial resistance

Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms


Biocon included in S&P Global Sustainability Yearbook 2024
Sustainability | February 20, 2024

Biocon included in S&P Global Sustainability Yearbook 2024

Sustainability is integral to Biocon's business purpose


Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
News | February 16, 2024

Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr

he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business